The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.
Bert H. O'Neil
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Manuel R. Modiano
No relevant relationships to disclose
Jean-Pascal H. Machiels
No relevant relationships to disclose
Melissa Jo Versola
No relevant relationships to disclose
Jeff Paul Hodge
No relevant relationships to disclose
Karen Sawarna
No relevant relationships to disclose
Nielson Tse
No relevant relationships to disclose